Literature DB >> 22211563

The value of apolipoprotein B/A1 ratio in the diagnosis of metabolic syndrome in a Korean population.

Chang Hee Jung1, Jenie Yoonoo Hwang, Ji Hee Yu, Mi Seon Shin, Sung Jin Bae, Joong-Yeol Park, Hong-Kyu Kim, Woo Je Lee.   

Abstract

OBJECTIVE: The ratio of apolipoprotein B (apoB) to apolipoprotein A1 (apoA1) has been reported to be associated with the metabolic syndrome (MetS). However, the optimal cut-off value of apoB/A1 ratio for detecting subjects with MetS has remained undetermined. In the present study, we aimed to investigate whether apoB/A1 ratio can be an indicator of MetS and to determine the optimal cut-off value of apoB/A1 ratio in detecting subjects with MetS in a Korean population.
DESIGN: This cross-sectional study was conducted at the Asan Medical Center, Seoul, Republic of Korea. SUBJECTS AND MEASUREMENTS: We collected the data of 10,940 subjects who participated in a routine health screening examination regarding conventional risk factors and serum levels of apoB and apoA1.
RESULTS: The odds for MetS were significantly higher in the highest compared with the lowest apoB/A1 ratio quartiles, after adjustment for confounding variables, in both men [odds ratio (OR) = 4·07, 95% CI = 3·42-4·84] and women (OR = 8·41, 95% CI = 5·85-12·08). The optimal apoB/A1 ratio cut-off value for the detection of MetS was 0·65, which had a sensitivity of 63·5% and a specificity of 61·3% (area under the curve = 0·67, 95% CI = 0·66-0·68, P < 0·001) in men and 0·62, which had a sensitivity of 67·9% and a specificity of 61·9% (area under the curve = 0·70, 95% CI = 0·69-0·71, P < 0·001) in women.
CONCLUSIONS: These results suggest that apoB/A1 ratio is independently associated with MetS and that an apoB/A1 ratio >0·65 in men and 0·62 in women is a marker of MetS independent from conventional risk factors.
© 2012 Blackwell Publishing Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22211563     DOI: 10.1111/j.1365-2265.2012.04329.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  6 in total

1.  Predictive value of serum apolipoprotein B/apolipoprotein A-I ratio in metabolic syndrome risk: a Chinese cohort study.

Authors:  Yu-Ching Chou; Jen-Chun Kuan; Chyi-Huey Bai; Tsan Yang; Wan-Yun Chou; Po-Chien Hsieh; San-Lin You; Lee-Ching Hwang; Chien-Hua Chen; Cheng-Yu Wei; Chien-An Sun
Journal:  Endocrine       Date:  2014-10-12       Impact factor: 3.633

2.  The nonlinear association between apolipoprotein B to apolipoprotein A1 ratio and type 2 diabetes.

Authors:  Yong Mao; Yang Xu; Leihong Lu
Journal:  Medicine (Baltimore)       Date:  2017-01       Impact factor: 1.889

3.  Apolipoprotein B/A1 Ratio as a Diagnostic Alternative to Triglycerides and HDL-Cholesterol for the Prediction of Metabolic Syndrome among Hypertensives in Kazakhstan.

Authors:  Alma Nurtazina; Dana Kozhakhmetova; Daulet Dautov; Aizhan Shakhanova; Vijay Kumar Chattu
Journal:  Diagnostics (Basel)       Date:  2020-07-23

4.  Apolipoprotein B/A1 Ratio Is Associated with Severity of Coronary Artery Stenosis in CAD Patients but Not in Non-CAD Patients Undergoing Percutaneous Coronary Intervention.

Authors:  Rui Hua; Yijun Li; Wenyuan Li; Zhen Wei; Zuyi Yuan; Juan Zhou
Journal:  Dis Markers       Date:  2021-12-18       Impact factor: 3.434

5.  The value of Apolipoprotein B/Apolipoprotein A1 ratio for metabolic syndrome diagnosis in a Chinese population: a cross-sectional study.

Authors:  Fangyuan Jing; Yingying Mao; Jing Guo; Zhenyu Zhang; Yingjun Li; Zhenhua Ye; Ye Ding; Jianbing Wang; Mingjuan Jin; Kun Chen
Journal:  Lipids Health Dis       Date:  2014-05-14       Impact factor: 3.876

6.  The Apolipoprotein B/A1 Ratio is Associated With Metabolic Syndrome Components, Insulin Resistance, Androgen Hormones, and Liver Enzymes in Women With Polycystic Ovary Syndrome.

Authors:  Hui He; Jiaxing Feng; Shike Zhang; Yu Wang; Jian Li; Jingshu Gao; Jing Cong; Yi Gong; Xiaoke Wu
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-05       Impact factor: 5.555

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.